TRILC TURK İLAÇ VE SERUM SANAYİ A.Ş. Stock
Türk İlaç ve Serum Sanayi A.Ş., ilaç ve serum üretimi alanında faaliyet gösteren bir şirkettir. Sağlık sektörüne yönelik ürünleriyle önemli bir oyuncudur.
| Period | Revenue | EBITDA | Net Income |
|---|---|---|---|
| 2026 Q1 | 1.4B | 272.8M | 200.7M |
| 2025 Q4 | 1.8B | 576.5M | -394.0M |
| 2025 Q3 | 1.3B | 324.3M | 73.2M |
| 2025 Q2 | 770.6M | 151.7M | -267.4M |
| 2025 Q1 | 642.6M | 90.3M | -307.9M |
| 2024 Q4 | 879.6M | 184.0M | 81.6M |
| 2024 Q3 | 565.7M | 230.8M | 5.8M |
| 2024 Q2 | 774.5M | 62.6M | 89.7M |
| Period | P/E (TTM) | TTM Net Income | E/P Quarterly | E/P Annual (TTM) |
|---|---|---|---|---|
| 2026 Q1 | — | -387.4M TRY | 0.0123 | -0.0237 |
| 2025 Q4 | — | -896.1M TRY | -0.0236 | -0.0537 |
| 2025 Q3 | — | -420.5M TRY | 0.0031 | -0.0179 |
| 2025 Q2 | — | -487.8M TRY | -0.0134 | -0.0244 |
| 2025 Q1 | — | -130.8M TRY | -0.0132 | -0.0056 |
| 2024 Q4 | 116.6 | 148.9M TRY | 0.0047 | 0.0086 |
| 2024 Q3 | — | -2.1M TRY | 0.0003 | -0.0001 |
| 2024 Q2 | 172.1 | 145.7M TRY | 0.0036 | 0.0058 |
| Period | Net Margin | Gross Margin | ROE | ROA | Debt/Equity | Rev. Growth (YoY) |
|---|---|---|---|---|---|---|
| 2026 Q1 | 14.5% | 25.3% | — | 9.5% | — | +116.1% |
| 2025 Q4 | -21.3% | 42.2% | -97.1% | -22.9% | 1.20 | +110% |
| 2025 Q3 | 5.7% | 33.2% | 15.3% | 4.8% | 0.68 | +126% |
| 2025 Q2 | -34.7% | 29.8% | -64.1% | -20.9% | 0.86 | -0.5% |
| 2025 Q1 | -47.9% | 25.6% | -68.1% | -27.2% | 0.71 | +84.7% |
| 2024 Q4 | 9.3% | 24.4% | 17% | 8.2% | 0.67 | +0.3% |
| 2024 Q3 | 1% | 51.6% | 1.3% | 0.7% | 0.71 | +29.8% |
| 2024 Q2 | 11.6% | 16.9% | 22.4% | 10.6% | 0.68 | +193.8% |
| Period | P/B |
|---|---|
| 2026 Q1 | 8.24 |
| 2025 Q4 | 10.28 |
| 2025 Q3 | 12.31 |
| 2025 Q2 | 12.00 |
| 2025 Q1 | 12.86 |
| 2024 Q4 | 9.03 |
| 2024 Q3 | 12.41 |
| 2024 Q2 | 15.68 |
What is the TRILC stock price?
The current price of TRILC is 1.50 TRY. (2026-07-17)
What is the TRILC E/P ratio?
The annual (TTM) E/P ratio of TRILC is -0.0237. Market cap: 16.4B TRY.
What sector is TRILC in?
TRILC (TURK İLAÇ VE SERUM SANAYİ A.Ş.) operates in the Kimya ve Petrokimya sector.
What is the TRILC P/B ratio?
The P/B (Price-to-Book) ratio of TRILC is 8.24.
TRILC Stock Analysis — Borsa Istanbul
This page provides a comprehensive analysis of TRILC (TURK İLAÇ VE SERUM SANAYİ A.Ş.), a company listed on Borsa Istanbul in the Kimya ve Petrokimya sector. The current share price, daily percentage change, and trading volume are updated at the end of each trading session using official BIST data.
Momentum and Technical Indicators
Short-term and medium-term momentum indicators for TRILC are calculated using 21-day and 63-day return windows. The 21-day Sortino ratio measures risk-adjusted performance by penalizing only downside volatility, providing a cleaner signal than standard deviation-based metrics. Annualized volatility and 252-day (one-year) momentum are also displayed to help investors assess both trend strength and risk characteristics of TRILC relative to its sector peers.
Fundamental Metrics
Key valuation ratios include the Earnings-to-Price (E/P) ratio calculated on both quarterly and trailing twelve-month (TTM) bases, the Price-to-Book (P/B) ratio derived from the most recent balance sheet equity, and market capitalization. Financial health indicators such as ROE (Return on Equity), ROA (Return on Assets), net profit margin, gross margin, and debt-to-equity ratio are sourced from the latest disclosed quarterly financial statements filed with KAP (Public Disclosure Platform).
Sector Comparison
TRILC is compared against other stocks in the Kimya ve Petrokimya sector across momentum, valuation, and profitability dimensions. The sector comparison table ranks TRILC against its peers using percentile scores, making it easy to identify whether the stock is relatively cheap (high E/P), growing faster (high momentum), or more profitable (high ROE) compared to the sector median. All data is refreshed daily and financial ratios are updated each quarter after earnings disclosures.